Subcutaneous immunoglobulin therapy in pediatric primary antibody deficiency

Meredith L. Moore*, James M. Quinn

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Subcutaneous immunoglobulin (SCIG) therapy is recognized as a standard treatment for primary antibody deficiency. SCIG is efficacious for the prevention of infections and is associated with a lower risk of systemic side effects, improved quality of life for patients and families and is preferred by children when compared with intravenous immunoglobulin replacement. For pediatric patients, SCIG is an ideal treatment modality that affords children and families more freedom and less disruption of important childhood activities. This article reviews the characteristics of SCIG to provide the pediatric practitioner with an understanding of the experiences their patients receiveing SCIG may encounter.

Original languageEnglish
Pages (from-to)231-240
Number of pages10
JournalPediatric Health
Issue number3
StatePublished - 2009
Externally publishedYes


  • Hypogammaglobulinemia
  • Immune deficiency
  • Immunodeficiency
  • Intravenous immunoglobulin
  • Primary antibody deficiency
  • SCIG
  • Subcutaneous immunoglobulin


Dive into the research topics of 'Subcutaneous immunoglobulin therapy in pediatric primary antibody deficiency'. Together they form a unique fingerprint.

Cite this